Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: vestor who wrote (1339)	6/22/1999 10:28:00 AM
From: Jaidev Sharma	Read Replies (1) \| Respond to of 1837

I got a letter from Duramed, dated May 17, yesterday (perhaps a similar letter went out to all the stockholders) stating the vision for Duramed. It states that: - "On May 12, we made our first shipments of Cenestin -- well ahead of the schedule we set.." - "We also look forward to additional product approvals within the next 90 days." - "We believe that our goal of an annualized sales rate for Cenestin of $100 million within 15-18 months after the product launch is achievable". They also talk about their association with Cardinal Health. Apparently, Cardinal is also trying to market Cenestin direct-to-physicians. Duramed also has a clause whereby they can absorb the new Cenestin sales force into Duramed if they want. Everything looks promising and the company seems to be mentally prepared to deliver the goods now. So I am expecting a steady rise in the stock price in the next 6 months. They also state that: -"When Cenestin approval was received, we anticipated it will bring material improvement in out operating performance in the 4th qtr and beyond, keeping in mind that there will be expenses associated with the product launch that occur before the anticipated revenue stream is initiated." This could mean not-very-impressive figures this qtr. Jaidev.